Biohaven looks to seize a new opportunity
The post-Pfizer pipeline looks disparate, but the group insists there is a method to its fast-follower approach.
Nimbus hopes to strike thrice
But the group has chosen the tough immuno-oncology space for its third attempt to woo the big players.
Novocure aims to plough a new field
Lung cancer approval for the group’s electric fields-based therapy could come this year, but Novocure has broader solid tumour ambitions.
Astrazeneca gets personal
A collaboration this week with the blood testing specialist Capitainer underlines the big pharma’s ambition to have a diagnostic linked with every pipeline project.
Anthos doubles down on its novel blood thinner
The group continues its niche-targeting strategy with abelacimab’s latest pivotal trial.
Rocket is bringing lenti back
The gene therapy player survived 2022 relatively unscathed, but big tests remain.
Developers take another shot at an Alzheimer's vaccine
But the current leader, Vaxxinity, will have to convince its doubters if it is to hook a partner.
Nimbus hopes to best Bristol’s Sotyktu
Nimbus aims to push Tyk2 inhibition to the limit with its more selective project, but others have a similar idea.
Beta Bionics and the promise of autonomy
A simpler diabetes tech is in the offing, but some patients are yet to be convinced that a device knows best.
